Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Shilpa M. Patel"'
Publikováno v:
The Scientific World Journal, Vol 7, Pp 1140-1148 (2007)
Tenofovir is an acyclic nucleotide analogue reverse transcriptase inhibitor that is commonly prescribed as part of a highly active antiretroviral therapy (HAART) regimen in HIV-infected patients. Although it is generally well tolerated, renal insuffi
Externí odkaz:
https://doaj.org/article/43dbb70c0d2c44e5a4a1c7c9c5610ffd
Publikováno v:
International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 12:1326-1331
Background: To find the effect of time interval between completion of neo adjuvant chemotherapy to the starting of adjuvant chemotherapy on the RFS and OS of patients with advanced ovarian cancers. Methods: It is a retrospective study of 170 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9252460f7a217008b8b8802bb919dbff
https://doi.org/10.18203/2320-1770.ijrcog20231217
https://doi.org/10.18203/2320-1770.ijrcog20231217
Autor:
Harsha Panchal, Shilpa M. Patel, Ava D. Desai, Meeta Mankad, Pabashi Poddar, Rajnish Tiwari, Ruchi S. Arora
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 41:345-350
Aims: The aim of this study is to identify clinicopathological features associated with increased morbidity and mortality in cases of “ultra-high risk” gestational trophoblastic neoplasia (GTN) and to compare initial low-dose etoposide-cisplatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c3a9669b900c897ed82a757d0b5e75e
https://doi.org/10.4103/ijmpo.ijmpo_235_18
https://doi.org/10.4103/ijmpo.ijmpo_235_18
Autor:
Bijal M. Patel, Garima Pandey, Pariseema Dave, Ruchi S. Arora, Chetna Parekh, Shilpa M. Patel, Dimpy Begum
Publikováno v:
Turkish Journal of Obstetrics and Gynecology, Vol 17, Iss 1, Pp 46-51 (2020)
Turkish Journal of Obstetrics and Gynecology
Turkish Journal of Obstetrics and Gynecology
Objective Malignant melanoma of the genital tract comprises 3% of all melanomas afflicting females. They are characterized by poor prognosis with 5-year survival of 0-25% and high incidence for distant metastasis. This study was performed to assess v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::180d2887c8ed3436ab6d32ac383d6d24
https://doaj.org/article/8296dc2dad434864a4cbe4f3496cb761
https://doaj.org/article/8296dc2dad434864a4cbe4f3496cb761
Autor:
Shilpa M. Patel, Pariseema Dave, Sangeetha Amin, Ruchi S. Arora, Pabashi Poddar, Chetana D. Parekh
Publikováno v:
Obstetrics & Gynecology Science
Obstetrics & Gynecology Science, Vol 63, Iss 2, Pp 158-163 (2020)
Obstetrics & Gynecology Science, Vol 63, Iss 2, Pp 158-163 (2020)
Objective This study aimed to study the patterns of recurrence in surgically treated cases of vulvar cancer (VC) and determine the factors associated with recurrence, with a special emphasis on lymph node ratio (LNR). Methods This retrospective study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38babad02f244c9982225be968117976
http://europepmc.org/articles/PMC7073358
http://europepmc.org/articles/PMC7073358
Autor:
Monisha Gupta, Pariseema Dave, Meeta Mankad, Ava D. Desai, Shilpa M. Patel, Rajneesh Tiwari, Ruchi S. Arora
Publikováno v:
South Asian Journal of Cancer
South Asian Journal of Cancer, Vol 09, Iss 01, Pp 30-33 (2020)
South Asian Journal of Cancer, Vol 09, Iss 01, Pp 30-33 (2020)
Aim: The aim of the study is to evaluate percent fall in CA-125 levels after neoadjuvant chemotherapy (NAC) and preoperative CA-125 value to predict surgical and survival outcomes in women with advanced-stage epithelial ovarian cancer (EOC). Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2af307332f681e7287812637e866bd4
http://europepmc.org/articles/PMC6956573
http://europepmc.org/articles/PMC6956573
Publikováno v:
International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 11:1531
Background: The current study was performed with an objective to evaluate the diagnostic accuracy of HE4 (human epididymis protein) and ROMA in prediction of ovarian cancer in patients with pelvic mass and to compare HE4 and ROMA with CA-125, and RMI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e2c481953dfe2fc571f5f45eaaa22f4
https://doi.org/10.18203/2320-1770.ijrcog20221289
https://doi.org/10.18203/2320-1770.ijrcog20221289
Autor:
Bijal M. Patel, Garima Pandey, Chetana D. Parekh, Pariseema Dave, Ruchi S. Arora, Shilpa M. Patel
Publikováno v:
Indian Journal of Gynecologic Oncology. 18
The prognostic nutrition index (PNI) had been shown to be prognostic in various gastrointestinal and head neck malignancies. The aim of this study was to investigate the significance of PNI in advanced ovarian cancer with respect to clinical characte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9044d591f7eefc8ee1061c6c00e3221
https://doi.org/10.1007/s40944-020-00435-2
https://doi.org/10.1007/s40944-020-00435-2
Publikováno v:
Indian Journal of Gynecologic Oncology. 18
Endometrial carcinoma is seen usually in the postmenopausal age. There are only case reports in the women aged 30 years or less. The aim was to evaluate endometrial carcinoma in women aged 30 years or younger and share our experience in the managemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f47a57c6f5991e9f23edbeea6e31a4f3
https://doi.org/10.1007/s40944-020-00403-w
https://doi.org/10.1007/s40944-020-00403-w
Publikováno v:
Indian Journal of Gynecologic Oncology. 18
Endometrial carcinoma is the commonest malignancy of female genital tract in the developed world. No widely accepted screening test exists for endometrial cancer. However, cervical cytology may be useful in predicting endometrial disease. The aim of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5843610e9b26626bbc9f4977f2a30c6
https://doi.org/10.1007/s40944-020-0380-4
https://doi.org/10.1007/s40944-020-0380-4